---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-208910"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T23:05:40.045562+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MannKind Q1 total revenue $90.2M (+15% YoY); Furoscix adds $15.5M; cash $134M

## Summary
- Total revenue $90.2M (+15% YoY); royalties from Tyvaso DPI up 9% to $32.7M.
- Furoscix net sales $15.5M (first full Q1 post-scPharma acquisition); Afrezza $15.3M (+3%).
- SG&A surged 116% to $54.1M driven by launch prep for Afrezza pediatric and Furoscix ReadyFlow.
- Cash and investments $134M; settled $36.3M convertible notes for $35.5M cash + 569K shares.
- Key PDUFA dates: Afrezza pediatric May 29; Furoscix Autoinjector July 26; nintedanib DPI Phase 2 enrollment Q2.

## SEC filing metadata
- accession: 0001193125-26-208910
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/0001193125-26-208910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/mnkd-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-208910
- JSON: https://secwatch.observer/filing/0001193125-26-208910.json
- Plain text: https://secwatch.observer/filing/0001193125-26-208910.txt

## Source-grounded claims
- claim_id: 75b5af3643bc72998435dc03552099db852c4f07
  claim: MANNKIND CORP reported the first quarter of 2026 results: revenue $90,171.
  evidence_excerpt: 386 3 % Furoscix 15,493 — 15,493 N/A V-Go 3,141 4,086 (945 ) (23 %) Collaborations and services 23,515 29,376 (5,861 ) (20 %) Royalties 32,749 30,005 2,744 9 % Total revenues $ 90,171 $ 78,354 $ 11,817 15 % Total revenues for the first quarter of 2026 increased compared to the same period in the prior year due to higher revenue from royalties and commercial
  evidence_url: https://www.sec.gov/Archives/edgar/data/899460/000119312526208910/0001193125-26-208910-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.